NLS Pharma Inc.   Report issue

For profit Phase 3
Founded: Stans Switzerland (2015)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02808104
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

NLS Pharmaceutics

Active Ingredients

Drugs in Phase 3 Trials (1)

mazindol (sanorex) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Hyperkinesis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1